• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌的诊断与治疗。2007年科尔多瓦共识

Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007.

作者信息

de la Haba-Rodríguez Juan, Alba Emilio, Barnadas Agustí, Bayo Eloisa, Llombart Antonio, Lluch Ana, Martín Miguel, Moreno-Nogueira José Andrés, Pérez Manga Gumersindo, Rodríguez-Lescure Alvaro, Aranda Enrique

机构信息

Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.

出版信息

Clin Transl Oncol. 2008 Sep;10(9):552-9. doi: 10.1007/s12094-008-0250-y.

DOI:10.1007/s12094-008-0250-y
PMID:18796372
Abstract

Many important studies have changed the perspective from which breast cancer is approached, and they may change what have to date been the standards applicable to the diagnosis and treatment of breast cancer. In 2007, just over 200 oncologists from all over Spain met in Cordoba in order to review the latest evidence related to breast cancer and reach a consensus on the most important aspects of its diagnosis and treatment in different clinical situations: neoadjuvance, adjuvance and advanced disease. In view of these important changes, opinions on some specific aspects may be varied and all are justified. This document represents a review of the current state of the evidence.

摘要

许多重要研究改变了人们对乳腺癌的研究视角,并且可能会改变迄今为止适用于乳腺癌诊断和治疗的标准。2007年,来自西班牙各地的200多名肿瘤学家齐聚科尔多瓦,共同审视与乳腺癌相关的最新证据,并就不同临床情况下(新辅助治疗、辅助治疗和晚期疾病)乳腺癌诊断和治疗的最重要方面达成共识。鉴于这些重要变化,对于某些特定方面的观点可能会有所不同,且都是合理的。本文献对当前证据状况进行了综述。

相似文献

1
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007.乳腺癌的诊断与治疗。2007年科尔多瓦共识
Clin Transl Oncol. 2008 Sep;10(9):552-9. doi: 10.1007/s12094-008-0250-y.
2
[Third revision of the National Consensus on Diagnosis and Treatment of Breast Cancer (second of three parts)].《乳腺癌诊疗全国共识(第三次修订版)》(三部分之二)
Ginecol Obstet Mex. 2010 Feb;78(2):138-50.
3
New challenges in multimodal workout of locally advanced breast cancer.局部晚期乳腺癌多模式治疗的新挑战
Surgeon. 2017 Dec;15(6):372-378. doi: 10.1016/j.surge.2017.05.006. Epub 2017 Jun 16.
4
[Development of guidelines and clinical practice for breast cancer].[乳腺癌指南与临床实践的制定]
Zhonghua Wai Ke Za Zhi. 2020 Feb 1;58(2):85-90. doi: 10.3760/cma.j.issn.0529-5815.2020.02.002.
5
[Breast cancer: figures and facts].
Wien Med Wochenschr. 2001;151(21-23):548-51.
6
Current decisions on neoadjuvant chemotherapy for early breast cancer: Experts' experiences in the Netherlands.当前早期乳腺癌新辅助化疗决策:荷兰专家的经验。
Patient Educ Couns. 2018 Dec;101(12):2111-2115. doi: 10.1016/j.pec.2018.07.012. Epub 2018 Jul 18.
7
[Clinical practice guideline for breast cancer].[乳腺癌临床实践指南]
Nihon Rinsho. 2007 Jun 28;65 Suppl 6:175-81.
8
[Breast cancer treatment].[乳腺癌治疗]
Duodecim. 2005;121(3):317-8.
9
Critical decision-making in radiotherapy for early stage breast cancer in a neo-adjuvant treatment era.新辅助治疗时代早期乳腺癌放疗中的关键决策
Expert Rev Anticancer Ther. 2017 May;17(5):481-485. doi: 10.1080/14737140.2017.1305897. Epub 2017 Mar 16.
10
[Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico].[墨西哥一家拥有大众健康保险的三级医疗机构的乳腺癌治疗评估]
Rev Invest Clin. 2012 Jan-Feb;64(1):9-16.

本文引用的文献

1
Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer.从乳腺癌的辅助性紫杉烷类药物治疗及内分泌反应性中获益。
Breast. 2007 Dec;16 Suppl 2:S127-31. doi: 10.1016/j.breast.2007.09.001. Epub 2007 Oct 17.
2
Individualization of therapy using Mammaprint: from development to the MINDACT Trial.使用Mammaprint进行治疗个体化:从研发到MINDACT试验
Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55.
3
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
新辅助曲妥珠单抗联合紫杉醇和表柔比星的疗效与安全性:纪念斯隆凯特琳癌症中心经验的回顾性分析
Cancer. 2007 Sep 15;110(6):1195-200. doi: 10.1002/cncr.22895.
4
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.绝经后雌激素受体阳性乳腺癌患者中一线内分泌治疗与化疗的2期随机试验。
Cancer. 2007 Jul 15;110(2):244-54. doi: 10.1002/cncr.22789.
5
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.一项III期试验,比较多柔比星联合环磷酰胺与多西他赛联合环磷酰胺作为可手术乳腺癌辅助治疗的效果。
J Clin Oncol. 2006 Dec 1;24(34):5381-7. doi: 10.1200/JCO.2006.06.5391.
6
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.序贯应用以表柔比星为基础的辅助化疗和多西他赛治疗淋巴结阳性乳腺癌患者:FNCLCC PACS 01试验
J Clin Oncol. 2006 Dec 20;24(36):5664-71. doi: 10.1200/JCO.2006.07.3916. Epub 2006 Nov 20.
7
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.组织学分级的基因重新分类界定了乳腺癌的新临床亚型。
Cancer Res. 2006 Nov 1;66(21):10292-301. doi: 10.1158/0008-5472.CAN-05-4414.
8
Gene expression profiling in breast cancer.乳腺癌中的基因表达谱分析
Ann Oncol. 2006 Sep;17 Suppl 10:x259-62. doi: 10.1093/annonc/mdl270.
9
NSABP study confirms oncotype DX predicts chemotherapy benefit in breast cancer patients.
Oncology (Williston Park). 2006 Jun;20(7):789-90.
10
Primary systemic therapy of breast cancer.乳腺癌的原发性全身治疗
Oncologist. 2006 Jun;11(6):574-89. doi: 10.1634/theoncologist.11-6-574.